These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34281421)

  • 1. Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.
    Rao VV; Godin CS; Lacy MJ; Inglefield JR; Park S; Blauth B; Reece JJ; Ionin B; Savransky V
    Int J Toxicol; 2021 Oct; 40(5):442-452. PubMed ID: 34281421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
    Hopkins RJ; Kalsi G; Montalvo-Lugo VM; Sharma M; Wu Y; Muse DD; Sheldon EA; Hampel FC; Lemiale L
    Vaccine; 2016 Apr; 34(18):2096-105. PubMed ID: 26979136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeat-Dose Toxicity Study of a Lyophilized Recombinant Protective Antigen-Based Anthrax Vaccine Adjuvanted With CpG 7909.
    Savransky V; Lacy M; Ionin B; Skiadopoulos MH; Shearer J
    Int J Toxicol; 2019; 38(3):163-172. PubMed ID: 31179828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).
    Minang JT; Inglefield JR; Harris AM; Lathey JL; Alleva DG; Sweeney DL; Hopkins RJ; Lacy MJ; Bernton EW
    Vaccine; 2014 Nov; 32(50):6847-54. PubMed ID: 24530403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmental and reproductive safety evaluation of AV7909 anthrax vaccine candidate in rats.
    Mylchreest E; Smiley MA; Ballin JD; Blauth B; Shearer J; Reece J; Ionin B; Savransky V
    Birth Defects Res; 2021 Jan; 113(1):32-42. PubMed ID: 33067910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909.
    Autumn Smiley M; Sanford DC; Triplett CA; Callahan D; Frolov V; Look J; Ruiz C; Reece JJ; Miles A; Ruiz E; Ionin B; Shearer JD; Savransky V
    Vaccine; 2019 Oct; 37(43):6356-6361. PubMed ID: 31530467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
    Hopkins RJ; Daczkowski NF; Kaptur PE; Muse D; Sheldon E; LaForce C; Sari S; Rudge TL; Bernton E
    Vaccine; 2013 Jun; 31(30):3051-8. PubMed ID: 23701746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat Dose Toxicity Study of the AV7909 Anthrax Vaccine Candidate in Juvenile Rats.
    Zmarowski A; Ballin JD; Sharits J; Carrico K; Novak J; Shearer J; Blauth B; Ionin B; Reece J; Savransky V
    Int J Toxicol; 2020 Jul; ():1091581820941412. PubMed ID: 32691648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart.
    Shearer JD; Henning L; Sanford DC; Li N; Skiadopoulos MH; Reece JJ; Ionin B; Savransky V
    Vaccine; 2021 Jan; 39(1):1-5. PubMed ID: 33199078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.
    Savransky V; Shearer JD; Gainey MR; Sanford DC; Sivko GS; Stark GV; Li N; Ionin B; Lacy MJ; Skiadopoulos MH
    Vaccine; 2017 Sep; 35(37):4952-4959. PubMed ID: 28774566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
    Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
    Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.
    Peachman KK; Li Q; Matyas GR; Shivachandra SB; Lovchik J; Lyons RC; Alving CR; Rao VB; Rao M
    Clin Vaccine Immunol; 2012 Jan; 19(1):11-6. PubMed ID: 22089245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
    Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
    Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines.
    Perry MR; Ionin B; Barnewall RE; Vassar ML; Reece JJ; Park S; Lemiale L; Skiadopoulos MH; Shearer JD; Savransky V
    Vaccine; 2020 Feb; 38(10):2307-2314. PubMed ID: 32029323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax.
    Klinman DM; Currie D; Lee G; Grippe V; Merkel T
    Microbes Infect; 2007 Oct; 9(12-13):1478-83. PubMed ID: 17913545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BA3338, a surface layer homology domain possessing protein augments immune response and protection efficacy of protective antigen against Bacillus anthracis in mouse model.
    Kumar M; Puranik N; Varshney A; Tripathi N; Pal V; Goel AK
    J Appl Microbiol; 2020 Aug; 129(2):443-452. PubMed ID: 32118336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores.
    Chichester JA; Manceva SD; Rhee A; Coffin MV; Musiychuk K; Mett V; Shamloul M; Norikane J; Streatfield SJ; Yusibov V
    Hum Vaccin Immunother; 2013 Mar; 9(3):544-52. PubMed ID: 23324615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.
    Malik A; Gupta M; Mani R; Gogoi H; Bhatnagar R
    Front Immunol; 2018; 9():562. PubMed ID: 29616046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of BioThrax® and AV7909 anthrax vaccines in adults 66 years of age or older.
    Wolfe DN; Espeland EM; Gao Y; Lu D; Blatner G; Amass K; Horwith G; Tong XM; Hopkins R; David GL; Jepson BM; King JC
    Vaccine; 2020 Nov; 38(50):7970-7976. PubMed ID: 33129609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
    Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
    J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.